New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients
NCT ID NCT04414163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called IMC-001 in 23 adults with a rare lymphoma (NK/T-cell) that has returned or stopped responding to prior therapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive IMC-001 and are monitored for response and safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Gwangju, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Ulsan University Hospital
Ulsan, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Immunotherapy combo may outperform chemo in rare lymphoma
- Massive T-Cell lymphoma database aims to unlock new insights
- Engineered donor cells take aim at tough blood cancers in early trial
- Promising combo may slash radiation harm in rare lymphoma
- New hope for blood cancer patients in japan?